OTCM
MDBIF
Aug 27, Last price
0.03USD
Name
Medibio Ltd
Chart & performance
P/E
—
P/S
178.16
EPS
—
Vol. 1Y
—
Shs. 5Y
94.42%
Rev. 5Y
-35.96%
Div Yld LY
—
Div Yld TTM
—
Revenues
889k
+3,926.59%
Net income
-1m
L-59.71%
CFO
-848k
L-8.99%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Medibio Limited is a health technology firm dedicated to the identification and screening of mental health conditions, serving clients in Australia and the United States. The company provides mental well-being programs for corporations through its corporate health product line and also innovates solutions for the healthcare provider market. Founded in 1987, the enterprise was initially known as BioProspect Limited before rebranding to Medibio Limited in November 2014. Its headquarters are situated in Melbourne, Australia.
Key people
Chairman of the Board, Chief Executive Officer, Managing Director · since 2019
Adam Darkins
Deputy Chairman of the Board · since 2017
Jeremy Schroetter
Chief Technology Officer
Archie Defillo
Chief Medical Officer
S. Stapelberg
Marketing Executive · since 2014
Mathew Watkins
Joint Company Secretary · since 2018
Peter Carlisle
Lead Independent Director · since 2019
Lisa Ragen Ide
Non-Executive Director · since 2019
Liwanag Ojala
Non-Executive Director · since 2019
Lisa Wipperman Heine
Non-Executive Director · since 2019
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||